Table 2.

Randomized controlled trials of local treatment in patients with oligometastatic breast cancer

–	OLIGOMA (NCT04495309)	NRG-BR002 (NCT02364557)	STEREO-SEIN (NCT02089100)	OMIT (NCT04413409)	Chinese Academy of Sciences (NCT04646564)	LARA NCT04698252
Sample size	564 patients	402 patients (phase II/III)	280 patients	172 patients	170 patients	74 patients
Maximum number of metastatic lesions	5	4	5 (≤ 10 cm/≤ 50 ml)	3 (only lung or liver metastases, < 5 cm)	5 (≤ 5 cm)	4 (bone/lung/liver), ipsilateral cervical or contralateral axillary metastases
Setting	Any treatment line	First-line setting, maximum of 1 year after diagnosis of MBC	First-line metastatic setting, HR positive	First-line setting	Metachronous recurrence > 3 months after surgery	Stable disease after 6 months of systemic therapy; HR positive, HER2 negative
Type of local therapy	Radiotherapy	Radiotherapy, surgery	Radiotherapy	Surgery	Radiotherapy	Radiotherapy, surgery, radiofrequency ablation
Primary endpoint	PFS + QoL	PFS/OS	PFS	OS	PFS	PFS

HR hormone receptor, PFS progression-free survival, OS overall survival, QoL quality of life